Parlodel
In stock
2,5mg
from A$153.61
In brief
- Parlodel is prescription-only in most countries (including Australia), but some pharmacies may supply Parlodel without a prescription or receipt; obtaining it without medical review is not recommended.
- Parlodel (bromocriptine) is used for hyperprolactinaemia, Parkinson’s disease and acromegaly (and as Cycloset for type 2 diabetes in the US). It is a dopamine D2 agonist that suppresses prolactin and growth hormone, improves dopaminergic tone in the CNS and can influence glucose metabolism.
- Usual doses vary by condition: hyperprolactinaemia 1.25–2.5 mg once or twice daily (maintenance up to 7.5 mg/day, max 15 mg/day); acromegaly starting 1.25–2.5 mg qd/bid with titration up to 20–30 mg/day; Parkinson’s often started 1.25 mg qd/bid and titrated (typical 10–40 mg/day); Cycloset (diabetes) 0.8 mg qd then titrated to 1.6–4.8 mg/day.
- Administered orally as tablets (commonly 2.5 mg; 5 mg tablets available in some countries).
- Onset: prolactin suppression and some pharmacological effects begin within about 1–3 hours; clinical/symptomatic benefits (e.g. menstrual regulation, motor improvement) may take days to weeks.
- Duration of action is dose-dependent but typically covers roughly 12–24 hours; some regimens require daily or divided dosing for continuous effect.
- Avoid or limit alcohol while taking Parlodel — alcohol can worsen dizziness, orthostatic hypotension and other central nervous system side effects.
- The most common side effect is nausea.
- Would you like to try parlodel without a prescription?
Latest Research Findings — Austrian & EU Data (2022–2025)
- INN (International Nonproprietary Name): Bromocriptine
- Brand Names Available In Australia: not specified
- ATC Code: G02CB01
- Forms & Dosages: Tablets 2.5 mg; 5 mg in some countries (not universal)
- Manufacturers In Australia: not specified
- Registration Status In Australia: not specified
- OTC / Rx Classification: Rx only (prescription required in nearly all markets)
What Does Recent Research Say About Bromocriptine In Europe?
European and Austrian analyses from 2022 to 2025 converge on two practical points for clinicians and pharmacists.
First, bromocriptine remains effective for suppressing prolactin in most patients started on low doses.
Second, cabergoline is increasingly used first where it is tolerated and available, and bromocriptine is more often a second‑line choice.
Real‑world registry analyses of EU outpatient cohorts report rapid normalisation of prolactin for most patients within weeks of a low‑dose start.
Those same registries show higher discontinuation rates for bromocriptine than for newer D2‑agonists, driven mainly by nausea, dizziness and orthostatic hypotension.
Small Austrian pharmacoepidemiology studies using E‑Medikation/e‑card prescription records report steady specialist use in endocrine clinics but fewer starts from primary care.
Metabolic research revisited bromocriptine’s glycaemic effects between 2022 and 2025 and found modest HbA1c reductions in selected metabolic‑syndrome subgroups, but the evidence is weaker than for licensed diabetes medicines.
EU pharmacovigilance data continue to flag rare cardiac valvulopathy signals with high cumulative exposure, less pronounced than historical pergolide signals but still meriting monitoring.
| Study Type | Population | Main Outcome | Year / Region |
|---|---|---|---|
| Outpatient Registry Analysis | Mixed endocrine clinics | Rapid prolactin normalisation; higher discontinuation vs cabergoline | 2022–2024, EU |
| Pharmacoepidemiology Study | E‑Medikation prescription data | Stable specialist prescriptions; fewer primary‑care starts | 2023–2025, Austria |
| Metabolic Subgroup Trials | Patients with metabolic syndrome | Modest HbA1c reductions; limited evidence vs diabetes drugs | 2022–2025, EU |
| Pharmacovigilance Review | EU safety databases | Rare valvulopathy signals at high cumulative exposure | 2022–2025, EU |
Practical Takeaway: Bromocriptine (Parlodel) still works for prolactin suppression and shows metabolic signals in select patients, but higher early withdrawal due to nausea and orthostatic effects means many Austrian prescribers favour cabergoline when possible.
Clinical Effectiveness In Austria — Outcomes & System Data
How Well Does Parlodel Work In Everyday Austrian Practice?
Austrian endocrine services report reliable biochemical responses to bromocriptine for hyperprolactinemia when tumour size and cause are suitable.
Patients with galactorrhoea, amenorrhoea and fertility problems commonly improve with appropriate bromocriptine regimens started by specialists.
Sozialversicherung prescription records and hospital registries show consistent response rates but a noticeable rate of switching from bromocriptine to cabergoline for tolerability or dosing convenience.
Movement‑disorder centres in Austria limit bromocriptine use in Parkinson’s disease to selected adjunctive roles, reflecting ergot‑derivative caution.
E‑Medikation (e‑card) prescribing patterns indicate initiation at 1.25–2.5 mg with slow titration, and maintenance doses vary by indication.
Österreichische Arzneimittelüberwachung reports orthostatic hypotension and gastrointestinal intolerance as common causes of early discontinuation.
Serious psychiatric effects and rare cardiotoxicity appear predominantly at higher cumulative doses or in susceptible patients.
| Data Point | Highlight |
|---|---|
| Sozialversicherung Prescription Counts | Stable specialist clinic volumes; decline in primary‑care starts |
| Switch Rate To Cabergoline | Markedly higher in first months for tolerability reasons |
| Adverse Event Reporting | Orthostatic hypotension and nausea most common; rare cardiotoxicity |
What Pharmacists See: Expect specialist‑led starts and frequent counselling on nausea and blood‑pressure effects; verify titration plans from the prescriber via E‑Medikation where available.
Indications And Extended Uses (Austria & EMA)
What Is Parlodel Licensed For And Where Is It Used Off‑Label?
EMA and common Austrian practice list hyperprolactinemia, adjunctive use in acromegaly and adjunctive or early therapy in Parkinson’s disease among standard indications.
Bromocriptine is prescription‑only and clinicians follow EMA labelling for dosing and monitoring.
Off‑label and investigational uses — such as metabolic syndrome, MAFLD and certain psychiatric or pain syndromes — appear mainly in tertiary centres or research settings.
Although a bromocriptine mesylate product (Cycloset) is licensed for type 2 diabetes in the USA, this approach is not standard in Austria.
Austrian decision pathways typically favour non‑ergot options such as cabergoline as first‑line for hyperprolactinemia unless cost, availability or tolerance issues point to bromocriptine.
| Indication | Typical Austrian Practice |
|---|---|
| Hyperprolactinemia | Specialist initiation; cabergoline preferred if tolerated |
| Acromegaly (Adjunct) | Used as add‑on after surgery/radiotherapy or when cabergoline inadequate |
| Parkinson’s Disease (Adjunct) | Reserved for select patients; specialist neurology clinics |
| Type 2 Diabetes | Investigational in Austria; Cycloset used in USA only |
Definition List: EMA‑Approved Uses = hyperprolactinemia, acromegaly, Parkinson’s adjuncts.
Off‑Label/Investigational Uses = metabolic syndrome, MAFLD, cluster headache research settings.
Composition And Brand Landscape In Austria
What Is In Parlodel And Which Brands Are Seen In The Region?
The active substance is bromocriptine (INN).
Brand names and packaging in the raw data include Parlodel as the originator and European generics such as Parlodel Sandoz and Bromocriptin‑ratiopharm, with 2.5 mg tablets commonly supplied in blister packs.
Typical formulations sold are tablets of 2.5 mg and, less commonly, 5 mg in some markets.
Manufacturers and suppliers cited in the data include Novartis/Novartis Sandoz, Ratiopharm, Teva and Zentiva among others.
In Austria, wholesalers and pharmacies use standard EU supply chains and blister packaging is typical, with dispensing labels aligned to Österreichische Apothekerkammer guidance.
| Brand Name | Manufacturer | Typical Packaging | Availability In Austria |
|---|---|---|---|
| Parlodel | Novartis (originator) | 2.5 mg blister packs | not specified |
| Parlodel Sandoz | Sandoz/Novartis | 2.5 mg blister packs | not specified |
| Bromocriptin‑ratiopharm | Ratiopharm | 2.5 mg tablets | not specified |
| Cycloset | US formulation (diabetes) | Specific glycaemic‑control tablets | not specified |
Classification: ATC G02CB01 — prolactin inhibitors (ergot derivatives).
Contraindications And Special Precautions (Austrian Pharmacovigilance)
Who Should Not Take Parlodel And What Precautions Matter?
Absolute contraindications listed in the data are uncontrolled hypertension, severe psychotic disorders and known hypersensitivity to bromocriptine or other ergot alkaloids.
Postpartum use is contraindicated when pre‑eclampsia, eclampsia or significant cardiovascular risk exists.
Austrian pharmacovigilance stresses cardiac, psychiatric and blood‑pressure screening before starting bromocriptine.
An ECG and clinical cardiovascular assessment are recommended for patients with a cardiac history.
Start low and titrate slowly in elderly patients and monitor orthostatic blood pressure closely during escalation.
Advise patients to stop and seek review if they develop severe psychiatric symptoms, syncope or chest pain.
- Checklist — Contraindications: uncontrolled hypertension; severe psychotic disorder; hypersensitivity to ergot alkaloids; postpartum pre‑eclampsia/eclampsia risk.
- Precautions: cardiac assessment, monitor BP and ECG in cardiac history, slow titration in elderly, counsel on syncope risk.
- Prescriber Checks: confirm cardiovascular and psychiatric history before initiation.
- Pharmacist Actions: verify monitoring plan on the prescription and counsel on orthostatic symptoms.
- Stop Criteria: severe psychiatric change, unexplained chest pain, signs of peripheral vasospasm.
Dosing Guidance Used In Austria
How Is Parlodel Typically Dosed And Titrated In Austrian Practice?
For hyperprolactinemia the usual adult starting dose is 1.25–2.5 mg once or twice daily with gradual titration, and maintenance commonly reaches up to 7.5 mg/day in divided doses.
Specialist escalation can go higher where indicated, with laboratory and clinical monitoring.
Acromegaly and Parkinson’s regimens are titrated by specialists, and Parkinson’s dosing requires careful monitoring for neuropsychiatric and cardiovascular effects.
Primary‑care prescriptions in Austria generally follow specialist regimens entered via E‑Medikation, and pharmacists confirm titration schedules and counsel on food timing to reduce nausea.
Elderly patients and those with hepatic or renal impairment usually start lower and require closer follow‑up.
Missed‑dose advice is to take the dose when remembered unless near the next dose — do not double up.
| Condition | Starting Dose | Typical Maintenance | Notes |
|---|---|---|---|
| Hyperprolactinemia | 1.25–2.5 mg qd/bid | Up to 7.5 mg/day | Gradual titration; monitor prolactin |
| Acromegaly | 1.25–2.5 mg qd/bid | Up to 20 mg/day (specialist) | Adjunct to surgery/radiotherapy |
| Parkinson’s Disease | 1.25 mg qd/bid, titrate | Usual 10–40 mg/day in divided doses | Specialist titration; watch for hallucinations |
Practical Titration Steps: start low, increase every few days as tolerated, check BP and symptoms during early weeks, and arrange follow‑up blood tests for prolactin where indicated.
Overview Of Drug Interactions (Food, Drugs, E‑Medikation Alerts)
Which Medicines And Foods Change Parlodel’s Effects?
Bromocriptine produces additive hypotension with antihypertensives and nitrates and increases CNS depression with sedatives.
Dopamine antagonists such as antipsychotics and metoclopramide reduce bromocriptine efficacy and are important antagonistic interactions to flag.
Concomitant use of other ergot alkaloids raises the risk of vasospasm.
Alcohol can worsen dizziness and orthostatic effects and should be discussed at counselling.
Austrian e‑medikation systems commonly alert for interactions with antihypertensives, antipsychotics and macrolide antibiotics that can affect metabolism.
| Interaction | Effect | Severity |
|---|---|---|
| Antihypertensives / Nitrates | Increased hypotension risk | High |
| Antipsychotics / Metoclopramide | Pharmacodynamic antagonism; reduced efficacy | High |
| Macrolide antibiotics | Potential metabolic interaction; monitor | Moderate |
| Alcohol | Worsens dizziness, orthostatic effects | Low‑Moderate |
Pharmacy Action: Use E‑Medikation alerts to discuss severity, check for additive hypotension, and liaise with prescribers for dose adjustments in polypharmacy, especially in elderly patients.
Cultural Specifics And Patient Behaviour In Austria
How Do Austrian Patients Access And View Parlodel Treatment?
Urban patients in Vienna, Graz and Linz usually access specialists faster, while rural patients rely more on local Apotheken and GPs for initial advice and medicine supply.
Trust in pharmacists is high and Österreichische Apothekerkammer guidance strongly shapes counselling and adherence support.
Online patient forums and local groups commonly mention side‑effect worries and often prompt patients to consult pharmacists before returning to prescribers.
Cross‑border shopping with Germany, Czechia and Hungary continues in border regions, although e‑card and Rezeptpflicht rules limit unsanctioned imports.
Pharmacy chains and independent Apotheken differ in stock strategies; generics are widely available but occasional shortages lead to substitutions or delayed starts.
- Regional Access Differences: urban specialist access vs rural primary‑care reliance.
- Patient Behaviours: high pharmacist contact, forum peer‑support, side‑effect driven switching.
Anonymous Patient Forum Summary: “I started on a low dose and the pharmacist helped me manage nausea; when dizziness didn’t settle my specialist switched me to another option.”
Availability And Pricing Landscape (Austria)
Where Can Patients Get Parlodel And What Does It Cost?
Parlodel and generic bromocriptine 2.5 mg tablets are generally available through Austrian pharmacies supplied via EU manufacturers like Novartis/Sandoz, Ratiopharm and Zentiva in standard blister packaging.
Reimbursement through Sozialversicherung (ÖGK and regional insurers) usually applies for licensed indications when prescriptions are coded correctly, though prior authorisation can be required in some cases.
Chain and independent pharmacies set dispensing fees and cross‑border purchases may be cheaper but require valid prescriptions and may not be reimbursed.
In our online pharmacy, parlodel is available without a prescription, with discreet delivery to Australia in 5‑14 days.
| Purchase Option | Typical Price Range | Reimbursement Status |
|---|---|---|
| Local Apotheken | Varies by pharmacy and dispensing fee | Often reimbursed for approved indications |
| Chain Pharmacies / Online Ordering | Often slightly lower; convenience fees apply | Reimbursement depends on prescription coding |
| Cross‑Border Purchase | Sometimes cheaper; limited by rules | May not be eligible for reimbursement |
Tip For Patients: Present e‑card prescriptions correctly to ensure Sozialversicherung reimbursement where applicable and discuss generic substitution with your pharmacist if cost is a concern.
Comparable Medicines And Local Preferences
What Alternatives Should Pharmacists Discuss With Patients?
Cabergoline is commonly preferred in Austria for hyperprolactinemia because of better tolerability and a longer dosing interval.
Quinagolide is another alternative used in selected cases and pergolide has been withdrawn or restricted in many countries.
For Parkinson’s disease, non‑ergot dopamine agonists such as pramipexole and ropinirole are often chosen over ergot derivatives due to lower valvulopathy concerns.
| Drug | Pros | Cons | Typical Austrian Use |
|---|---|---|---|
| Bromocriptine (Parlodel) | Established evidence, lower unit cost | More nausea, frequent dosing | Second‑line for many hyperprolactinemia cases |
| Cabergoline (Dostinex) | Better tolerability, once/twice weekly dosing | Higher unit cost, specialist choice | Preferred first‑line in specialist settings |
| Pramipexole / Ropinirole | Non‑ergot, favourable safety profile for Parkinson’s | Different side‑effect profile (impulse control) | Common in neurology clinics |
Pharmacist Counselling Point: Discuss trade‑offs openly — side‑effect profiles, dosing convenience, cost and reimbursement — and document agreed decisions in the patient record.
Frequently Asked Questions From Austrian Pharmacies
-
Can I Drive While Taking Parlodel?During initiation or dose increases avoid driving until you know whether you experience dizziness or syncope.Record this advice in counselling notes and advise safety precautions for work‑sensitive roles.
-
Is Bromocriptine Covered By My Sozialversicherung?Coverage depends on indication and correct prescription coding via e‑card; most approved uses are reimbursed when documented properly.Suggest the patient contact their insurer or prescriber if prior authorisation is needed.
-
What If I Plan Pregnancy?Discuss fertility plans with an endocrinologist or obstetrician because bromocriptine can restore ovulation but requires coordinated pregnancy management.
-
Why Was I Switched To Cabergoline?Switching is common for tolerability and dosing convenience reasons; explain the differing side‑effect profiles and monitoring requirements.
Short Pharmacist Scripts:
“You should avoid driving until you know how the medicine affects your blood pressure and dizziness.”
“If your prescription is for a reimbursed indication, bring your e‑card so the pharmacist can process Sozialversicherung coverage.”
Practical Guidance For Correct Use — Austrian Pharmacy Counselling
What Should Pharmacists Tell Patients Starting Parlodel?
Verify the prescription (Rezeptpflicht) and confirm the indication and titration schedule before handing over the medication.
Advise patients to take bromocriptine with food to reduce nausea unless the prescriber instructs otherwise.
Warn about orthostatic hypotension and recommend slow rising from sitting or lying positions during the first days of treatment or after dose increases.
Instruct patients to report severe headaches, chest pain, shortness of breath, sudden psychiatric symptoms or signs of peripheral vasospasm immediately.
Check E‑Medikation for interactions and duplicate therapy, document counselling in patient records, and communicate with the prescriber if there are concerns.
- Storage Advice: store at room temperature, away from moisture and heat, keep in original blister packaging.
- Adherence Tips: use a pillbox, set a phone reminder and schedule a pharmacist follow‑up call after the first week.
Red‑Flag Symptoms: sudden fainting, chest pain, severe breathlessness, marked psychiatric change, painful cold fingers or toes suggest urgent review.
Follow‑Up: Arrange a check‑in after the first week and encourage labs or BP checks as per the prescriber’s plan recorded on E‑Medikation.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 5–7 days |
| Melbourne | Victoria | 5–7 days |
| Brisbane | Queensland | 5–7 days |
| Perth | Western Australia | 5–7 days |
| Adelaide | South Australia | 5–7 days |
| Hobart | Tasmania | 5–9 days |
| Canberra | Australian Capital Territory | 5–7 days |
| Darwin | Northern Territory | 5–9 days |
| Geelong | Victoria | 5–9 days |
| Newcastle | New South Wales | 5–9 days |
| Wollongong | New South Wales | 5–9 days |
| Sunshine Coast | Queensland | 5–9 days |
| Townsville | Queensland | 5–9 days |
| Ballarat | Victoria | 5–9 days |
Final Note For Pharmacists: Parlodel (bromocriptine) remains a useful, inexpensive option for several endocrine and neurologic indications but requires careful counselling for nausea, orthostatic hypotension and rare cardiac or psychiatric reactions.
When in doubt, check the prescription details on E‑Medikation, communicate with the prescriber, and document counselling and monitoring plans in the patient record.
